The role of combined fludarabine, cyclophosphamide and rituximab chemoimmunotherapy in chronic lymphocytic leukemia: current evidence and controversies

被引：19
|
作者：
Skarbnik, Alan P. [1 ]
Faderl, Stefan [2 ]
机构：
[1] Hackensack Univ, Med Ctr, Div Lymphoma, John Theurer Canc Ctr,Blood & Marrow Transplantat, 92 Second St, Hackensack, NJ 07624 USA
[2] Hackensack Univ, Med Ctr, Div Leukemia, John Theurer Canc Ctr, Hackensack, NJ USA
来源：
THERAPEUTIC ADVANCES IN HEMATOLOGY | 2017年 / 8卷 / 03期
关键词：
chemoimmunotherapy; CLL; FCR; fludarabine; rituximab; PREVIOUSLY UNTREATED PATIENTS; LOW-DOSE FLUDARABINE; INITIAL THERAPY; OPEN-LABEL; AGENT; CHLORAMBUCIL; REGIMEN; FCR; CHEMOTHERAPY; VINCRISTINE;
D O I：
10.1177/2040620716681749
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Chemoimmunotherapy (CIT) has become a cornerstone in the treatment of patients with chronic lymphocytic leukemia (CLL). The combination of fludarabine, cyclophosphamide and rituximab (FCR) has emerged as the standard of care for therapy of previously untreated patients with CLL who are younger than 65 years and have no significant comorbidities. In this article, we review the role of FCR in the current treatment paradigm for CLL.
引用
收藏
页数：8
相关论文
共 50 条
  • [31] Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study
    Herling, Carmen D.
    Coombes, Kevin R.
    Benner, Axel
    Bloehdorn, Johannes
    Barron, Lynn L.
    Abrams, Zachary B.
    Majewski, Tadeusz
    Bondaruk, Jolanta E.
    Bahlo, Jasmin
    Fischer, Kirsten
    Hallek, Michael
    Stilgenbauer, Stephan
    Czerniak, Bogdan A.
    Oakes, Christopher C.
    Ferrajoli, Alessandra
    Keating, Michael J.
    Abruzzo, Lynne V.
    LANCET ONCOLOGY, 2019, 20 (11) : 1576 - 1586
  • [32] Role of rituximab in first-line treatment of chronic lymphocytic leukemia
    Bryan, Jeffrey
    Borthakur, Gautam
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2011, 7 : 1 - 11
  • [33] Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial
    Robak, Tadeusz
    Warzocha, Krzysztof
    Babu, K. Govind
    Kulyaba, Yaroslav
    Kuliczkowski, Kazimierz
    Abdulkadyrov, Kudrat
    Loscertales, Javier
    Kryachok, Iryna
    Kloczko, Janusz
    Rekhtman, Grygoriy
    Homenda, Wojciech
    Blonski, Jerzy Z.
    McKeown, Astrid
    Gorczyca, Michele M.
    Carey, Jodi L.
    Chang, Chai-Ni
    Lisby, Steen
    Gupta, Ira V.
    Grosicki, Sebastian
    LEUKEMIA & LYMPHOMA, 2017, 58 (05) : 1084 - 1093
  • [34] The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of Biosimilars
    Brown, Jennifer R.
    Cymbalista, Florence
    Sharman, Jeff
    Jacobs, Ira
    Nava-Parada, Pilar
    Mato, Anthony
    ONCOLOGIST, 2018, 23 (03) : 288 - 296
  • [35] Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia
    Abrisqueta, Pau
    Villamor, Neus
    Jose Terol, Maria
    Gonzalez-Barca, Eva
    Gonzalez, Marcos
    Ferra, Christelle
    Abella, Eugenia
    Delgado, Julio
    Garcia-Marco, Jose A.
    Gonzalez, Yolanda
    Carbonell, Felix
    Ferrer, Secundino
    Monzo, Encarna
    Jarque, Isidro
    Muntanola, Ana
    Constants, Mireia
    Escoda, Lourdes
    Calvo, Xavier
    Bobillo, Sabela
    Bruno Montoro, Jose
    Montserrat, Emili
    Bosch, Francesc
    BLOOD, 2013, 122 (24) : 3951 - 3959
  • [36] Rituximab in chronic lymphocytic leukemia
    James, Danelle F.
    Kipps, Thomas J.
    ADVANCES IN THERAPY, 2011, 28 (07) : 534 - 554
  • [37] Rituximab for chronic lymphocytic leukemia
    Robak, Tadeusz
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (04) : 503 - 515
  • [38] Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia
    Robak, Tadeusz
    Dmoszynska, Anna
    Solal-Celigny, Philippe
    Warzocha, Krzysztof
    Loscertales, Javier
    Catalano, John
    Afanasiev, Boris V.
    Larratt, Loree
    Geisler, Christian H.
    Montillo, Marco
    Zyuzgin, Ilya
    Ganly, Peter S.
    Dartigeas, Caroline
    Rosta, Andras
    Maurer, Joerg
    Mendila, Myriam
    Saville, M. Wayne
    Valente, Nancy
    Wenger, Michael K.
    Moiseev, Sergey I.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (10) : 1756 - 1765
  • [39] Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG-CLL4 (ML21283) trial
    Robak, Tadeusz
    Blonski, Jerzy
    Skotnicki, Aleksander Bartlomiej
    Piotrowska, Magdalena
    Wrobel, Tomasz
    Rybka, Justyna
    Kloczko, Janusz
    Bolkun, Lukasz
    Budziszewska, Bozena Katarzyna
    Walczak, Urszula
    Uss, Anatoly
    Fidecka, Marta
    Smolewski, Piotr
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2018, 100 (05) : 465 - 474
  • [40] Prolonged progression-free survival in patients with chronic lymphocytic leukemia receiving granulocyte colony-stimulating factor during treatment with fludarabine, cyclophosphamide, and rituximab
    Gruber, Michaela
    Fleiss, Karin
    Porpaczy, Edit
    Skrabs, Cathrin
    Hauswirth, Alexander W.
    Gaiger, Alexander
    Vanura, Katrina
    Heintel, Daniel
    Shehata, Medhat
    Einberger, Christine
    Thalhammer, Renate
    Fonatsch, Christa
    Jaeger, Ulrich
    ANNALS OF HEMATOLOGY, 2011, 90 (10) : 1131 - 1136
12345